See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: June 25, 2007

Atrial Fibrillation Osteoarthritis Multiple Sclerosis

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Atrial Fibrillation

This study will compare the safety and effectiveness of an investigational ablation catheter that uses light-energy to treat atrial fibrillation. Volunteers 18-65 who have failed to respond to drug treatment or find the side effects of standard medication intolerable may be eligible to participate.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat243.html.

-----

Osteoarthritis

Volunteers who have knee pain associated with osteoarthritis may qualify for this study of an investigational device. Volunteers 40-80 who have knee pain while standing or performing activity may be eligible.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat109.html.

-----

Multiple Sclerosis

This study for people with multiple sclerosis will evaluate the effects of an investigational drug on cognitive functions including memory and thinking skills. Participants will need to visit the study clinic approximately six times over a three-month period. Candidates 18-64 who have at least a 9th grade education and a diagnosis of MS (relapsing remitting or secondary progressive) may qualify.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat102.html.

-----

Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.